Microparticles and nanoparticles for drug delivery.

Microparticles and nanoparticles for drug delivery. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Microparticles and nanoparticles for drug delivery. Abstract Text:

Daniel S Kohane,

Particulate drug delivery systems have become important in experimental pharmaceutics and clinical medicine. The distinction is often made between micro- and nanoparticles, being particles with dimensions best described in micrometers and nanometers respectively. That size difference entails real differences at many levels, from formulation to in vivo usage. Here I will discuss those differences and provide examples of applications, for local and systemic drug delivery. I will outline a number of challenges of interest in particulate drug delivery.

Microparticles and nanoparticles for drug delivery. Publishing Authors By Initials

DS Kohane,

For similar natural sciences: chemistry: chemistry, physical: particle size research abstracts see: natural sciences: chemistry: chemistry, physical: particle size research

PUBMED ID PMID:

MEDLINE DATE:

Microparticles and nanoparticles for drug delivery. Journal Published:

PUBLICATION TYPE: Review

Journal: Biotechnology and bioengineering

VOLUME: 96

Page Numbers: 203-9

Journal Abbreviation: Biotechnol. Bioeng.

ISSN: 0006-3592

DAY: 1

MONTH: Feb

YEAR: 2007

Microparticles and nanoparticles for drug delivery. Information

Number of References: 33

LANGUAGE: eng

NlmUniqueID: 7502021

Microparticles and nanoparticles for drug delivery. Keywords Mesh Terms:

KEYWORDS: Particle Size

MESH TERMS:

Chemical & Substance for Abstract: Microparticles and nanoparticles for drug delivery. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Microparticles and nanoparticles for drug delivery.

AFFILIATION: Laboratory for Biomaterials and Drug Delivery, Bartlett Extension 413, Division of Critical Pediatric Care, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA. dkohane@partners.org

Country: United States

AGENCY: United States NIGMS

GRANT: GM073626

ACRONYM: GM

MEDLINETA: Biotechnol Bioeng

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Microparticles and nanoparticles for drug delivery Related Publications

• A set of genes previously implicated in the hypoxia response might be an important modulator in the rat ear tissue response to mechanical stretch.
• Absolute enrichment: gene set enrichment analysis for homeostatic systems.
• Analysis of gene expression in a developmental context emphasizes distinct biological leitmotifs in human cancers.
• Anti-inflammatory function of an in situ cross-linkable conjugate hydrogel of hyaluronic acid and dexamethasone.
• Antifungal hydrogels.
• Computational analysis of non-adherence and non-attendance using the text of narrative physician notes in the electronic medical record.
• DITTO - a tool for identification of patient cohorts from the text of physician notes in the electronic medical record.
• Dextran-based in situ cross-linked injectable hydrogels to prevent peritoneal adhesions.
• Dulxanthone A induces cell cycle arrest and apoptosis via up-regulation of p53 through mitochondrial pathway in HepG2 cells.
• Evidence of spatially bound gene regulation in Mus musculus: decreased gene expression proximal to microRNA genomic location.
• Follow-up study of adolescent girls with a history of premature pubarche.
• GenePING: secure, scalable management of personal genomic data.
• Identifying patient smoking status from medical discharge records.
• Local myotoxicity from sustained release of bupivacaine from microparticles.
• Microparticles and nanoparticles for drug delivery.
• Microparticles for inhalational delivery of antipseudomonal antibiotics.
• Optimal data entry by patients: effects of interface structure and design.
• PEFIOS: an expert closed-loop oxygenation algorithm.
• Peritoneal adhesion prevention with an in situ cross-linkable hyaluronan gel containing tissue-type plasminogen activator in a rabbit repeated-injury model.
• Perturbation of gene expression of the chromatin remodeling pathway in premature newborns at risk for bronchopulmonary dysplasia.
• Prevention of peritoneal adhesions with an in situ cross-linkable hyaluronan hydrogel delivering budesonide.
• Tectonic shifts in the health information economy.
• Tetrodotoxin for prolonged local anesthesia with minimal myotoxicity.
• The biocompatibility of mesoporous silicates.